Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Selecta Biosciences, Inc.

Home Clinical Trial Sponsors and OrganizationsSelecta Biosciences, Inc.

Selecta Biosciences, Inc.

ACTIVE

马萨诸塞州米德尔塞克斯县, Massachusetts, United Stateswww.selectabio.comPublic64 employeesEstablished: 2008-01-01

Part of Cartesian Therapeutics

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

7

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2008

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

5

71.4%

Phase 2

2

28.6%

Trial Status Distribution

Completed

6

85.7%

Suspended

1

14.3%

Clinical Trials

Trials sponsored by this organization (7)

A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA

Dec 20226 participants

A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy

May 2019170 participants

Safety and Pharmacodynamcis of SELA-070 Nicotine Vaccine in Smokers

May 201772 participants

Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

Oct 2016152 participants

Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels

Dec 201563 participants

Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels

May 201522 participants

Safety and Pharmacodynamics of SEL-068 Vaccine in Smokers and Non-Smokers

Nov 201182 participants

Approvals

No approval data available

News

Hyperuricemia Pipeline Shows Promise with 15+ Emerging Therapies in Development

- Global hyperuricemia pipeline comprises 12+ key companies developing 15+ treatment therapies across various clinical stages, according to DelveInsight's 2025 report. - Leading companies in hyperuricemia drug development include LG Chem, Shanton Pharma, InventisBio, Jiangsu HengRui Medicine, and Selecta Biosciences, with treatments spanning oral, intravenous, and subcutaneous administration routes. - A significant development occurred in December 2024 when Atom Therapeutics partnered with China Medical System Holdings to commercialize lingdolinurad (ABP-671), a novel URAT1 inhibitor for chronic gout and hyperuricemia in China.

On this page

Overview
Clinical Trials7
Approvals
News1

Back to Organizations